Vitamin E, alpha- and gamma-tocopherol, and prostate cancer release_rutztv7ozrcvfpzzbefyypkddm

by M A Moyad, S K Brumfield, K J Pienta

Published in Seminars in Urologic Oncology .

1999   Volume 17, Issue 2, p85-90

Abstract

Vitamin E is one of the most researched compounds in medicine. Vitamin E is actually a general name for potentially eight different compounds, so supplements can contain several forms and vitamin E in the diet also differs from the form found over the counter. There has been a strong interest in this supplement in the prostate cancer arena primarily because of a Finnish study that demonstrated a lower morbidity and mortality from this disease in men taking 50 mg of synthetic (alpha-tocopherol) vitamin E daily. In addition, observations from laboratory and clinical studies dealing with heart disease have found that gamma-tocopherol may also play a significant role in prevention; therefore, we decided to test the ability of this compound (versus synthetic vitamin E) to control the growth of a human prostate cancer cell line. Gamma-tocopherol was found to be superior to alpha-tocopherol in terms of cell inhibition in vitro. Both forms of vitamin E (and others) should be thoroughly evaluated in the future to provide the most effective chemoprevention information to the patient.
In text/plain format

Archived Content

There are no accessible files associated with this release. You could check other releases for this work for an accessible version.

Not Preserved
Save Paper Now!

Know of a fulltext copy of on the public web? Submit a URL and we will archive it

Type  article-journal
Stage   published
Year   1999
Language   en ?
PubMed  10332921
Container Metadata
Not in DOAJ
In Keepers Registry
ISSN-L:  1081-0943
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: cf49baef-a3db-4f5c-84e2-a356cb252944
API URL: JSON